@article{bdedcb149c564aaea2d5832b8bd4a1c4,
title = "Molecular imaging of cardiac amyloidosis",
abstract = "Transthyretin and light-chain amyloidosis are the 2 main causes of cardiac amyloidosis. Recent developments in molecular imaging have transformed our ability to diagnose transthyretin cardiac amyloidosis noninvasively and unmasked a hitherto unrecognized prevalence of the disease. This review summarizes the current and evolving imaging approaches, their molecular structural basis, and the gaps in imaging capabilities that have arisen as a result of parallel developments in pharmacotherapy delivering the first effective treatment options for this condition.",
keywords = "ATTR, Bone-seeking tracers, Cardiac amyloidosis, Molecular imaging, SPECT",
author = "Ahmad Masri and Syed Bukhari and Eisele, {Yvonne S.} and Prem Soman",
note = "Funding Information: Ahmad Masri received research funding from Pfizer and Akcea. Prem Soman received grant funding from Pfizer and is on the advisory board of Pfizer, Alnylam, and Eidos. Syed Bukhari is the current incumbent of a CA fellowship funded by Pfizer through a competitive national RFA. Yvonne Eisele and Prem Soman received support from the Vascular Medicine Institute, University of Pittsburgh. Yvonne Eisele received support from the National Institute on Aging under award number R00 AG050764. No other potential conflict of interest relevant to this article was reported. Publisher Copyright: COPYRIGHT {\textcopyright} 2020 by the Society of Nuclear Medicine and Molecular Imaging.",
year = "2020",
month = jul,
day = "1",
doi = "10.2967/jnumed.120.245381",
language = "English (US)",
volume = "61",
pages = "965--970",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "7",
}